Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/rheumatology/keaa068 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Vitality, viability, long-term clonogenic survival, cytotoxicity, cytostasis and lethality: what do they mean when testing new investigational oncology drugs?
Discov Oncol
January 2024
Experimental Pathology Unit, Department of Pathology, Faculty of Medicine and Health Sciences, McGill University, Montreal, QC, Canada.
In the field of experimental therapeutics for oncology purposes researchers are continuously evaluating the toxicity of novel treatment approaches against cancer cells. Within this topic of research, it is highly critical to define parameters of toxicity that denote when cancer cells are perturbed in their functionality by a new investigational drug. As the goal for these approaches is to achieve cellular demise, then what approaches to use and what do they mean in terms of assessing such cell death is of critical importance.
View Article and Find Full Text PDFEditorial Comment to Prognostic significance of subclassifying pathological T3 upper tract urothelial carcinoma: Results from a multicenter cohort study.
Int J Urol
February 2024
Department of Urology, Tokyo Women's Medical University Adachi Medical Center, Adachi-ku, Tokyo, Japan.
Comment on: Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum: reply.
Rheumatology (Oxford)
May 2020
Department of Medicine, University of Cambridge, Cambridge, UK.
Comment on: Subclassifying ANCA-associated vasculitis: a unifying view of disease spectrum.
Rheumatology (Oxford)
May 2020
Department of Internal Medicine, Université Paris-Descartes, Paris, France.
Subclassifying peripheral T-cell lymphoma NOS.
Blood
December 2019
Fondazione IRCCS Istituto Nazionale dei Tumori di Milano.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!